We've experienced the significant gaps in our collective ability, as a medical and research community, to access and understand disease-defining biology when it matters most. To address this, we've developed a simple blood test uncovers actionable disease-defining transcriptional biology. Our unique genome-wide platform profiles circulating chromatin and the DNA methylome to deliver resolution into the dynamic activity of individual genes and pathways in diseased tissues from just 1mL of plasma. By partnering with developers of new medicines and advancing our own diagnostic tests, we’re working towards a world where new medicine development efforts succeed more frequently, and where anyone can receive a minimally invasive diagnosis and treatment that’s precise to the biology of their disease.
Location: United States, Massachusetts, Boston
Employees: 11-50
Total raised: $57M
Founded date: 2021
Investors 1
| Date | Name | Website |
| 18.10.2023 | 5AM Ventur... | 5amventure... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 10.10.2023 | - | $57M | - |
Mentions in press and media 1
| Date | Title | Description |
| 10.10.2023 | Precede Biosciences Emerges From Stealth With $57M in Funding | Precede Biosciences, a Boston, MA-based biotechnology company providing a blood-based approach to revealing disease-defining transcriptional biology, emerged from stealth with $57M in funding since inception. Precede was co-founded through ... |